Zogenix Stock

Zogenix Liabilities

Delisted

The The Liabilities of Zogenix (ZGNX) as of Aug 9, 2026 is 289.52 M USD. In the previous year, The Liabilities was 281.46 M USD — a change of 2.86% (higher).

Liabilities

289.52 MUSD

YoY

2.86%

Last updated:

In 2026, Zogenix's total liabilities amounted to 289.52 M USD, a 2.86% difference from the 281.46 M USD total liabilities in the previous year.

Access this data via the Eulerpool API

Zogenix Stock analysis

What does Zogenix do? Zogenix Inc. is an American biotech company that specializes in the development and commercialization of drugs for the treatment of central nervous system disorders and pain. The company was founded in 2006 and is headquartered in Emeryville, California. In 2009, Zogenix Inc. brought its first product to market, the prescription painkiller Zohydro. Shortly after, in 2012, the company announced the approval of Sumavel DosePro, an innovative injection technology for the treatment of migraines. In 2018, the company completed a merger with California-based Modis Therapeutics. Together, they are developing drugs for rare genetic metabolic disorders. Zogenix has a promising business model, focusing on research and development and the marketing of true innovations in the CNS and pain field. The company aims to revolutionize the medical market with its medications, rather than simply replacing existing drugs. For this reason, Zogenix collaborates closely with leading institutes and research facilities to identify and develop new active ingredients. Zogenix is divided into various business segments, each specializing in the development of new drugs and therapies. One of Zogenix's main products is the Sumavel DosePro injection technology, which allows for quick and effective treatment of migraine attacks. Another important business area for Zogenix is the development of medications and therapies for the treatment of neuropsychiatric disorders. This includes ZX008 (Fenfluramine), an investigational drug for the treatment of Dravet syndrome, a rare form of epilepsy. The medication has already been approved in Europe and is currently being reviewed in the United States. Zogenix also focuses on the development of therapies for opioid and opiate-related disorders, as well as pain management. This includes the product Zohydro, which is a long-acting opioid painkiller. Zogenix offers a variety of prescription drugs and therapies targeting various neurological disorders and pain syndromes. The company's products aim to alleviate symptoms and address the underlying causes of the diseases. In summary, Zogenix is a biotech company specializing in the development and commercialization of drugs for the treatment of central nervous system disorders and pain. With a wide range of products and a promising business model, the company is focused on innovation in the medical industry. Zogenix Inc represents an important area of research and development for new medications in the future. Zogenix is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Zogenix's Liabilities

Zogenix's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Zogenix's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Zogenix's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Zogenix's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Zogenix’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Zogenix stock

The Liabilities of Zogenix is 289.52 M USD in 2026.

The Liabilities of Zogenix changed from 281.46 M USD to 289.52 M USD, representing a 2.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Zogenix since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Zogenix historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Zogenix

All Key Metrics — Zogenix